Sexual behaviour among women using intramuscular depot medroxyprogesteroneacetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial. Contraceptive use has complex effects on sexual behaviour and mood, including those related to reduced concerns about unintended pregnancy, direct hormonal effects and effects on endogenous sex , South Africa and Zambia seeking contraception were randomly assigned to intramuscular depot-medroxyprogesteroneacetate (DMPA-IM), the copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. Data collected for 12 to 18 months using 3-monthly behavioural questionnaires that relied on recall from the preceding 3 months, were used to estimate relative risk of post-baseline sex behaviours
Effects of injectable contraception with depot medroxyprogesteroneacetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial. Observational data suggest lower HIV risk with norethisterone enanthate (NET-EN) than with depo-medroxyprogesteroneacetate intramuscular (DMPA-IM) injectable
The injectable contraceptives depot medroxyprogesteroneacetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial. HIV acquisition risk with norethisterone (NET) enanthate (NET-EN) is reportedly less than for depo-medroxyprogesteroneacetate intramuscular (DMPA-IM
Bone density changes in young women in Uganda using tenofovir-based HIV preexposure prophylaxis and depot medroxyprogesteroneacetate contraception. Injectable depot medroxyprogesteroneacetate (DMPA) is the most common contraceptive choice among young women in Uganda, where HIV burden is high and HIV preexposure prophylaxis (PrEP) may be offered. For young women who choose to use both agents
Depot medroxyprogesteroneacetate concentrations in patients with and without use of anti-seizure medications. To measure plasma concentrations of medroxyprogesteroneacetate (MPA) in users with epilepsy treated with anti-seizure medications and compare these to MPA concentrations in those without epilepsy. For this multi-site cross-sectional study, we obtained a single blood sample from those
Oral medroxyprogesteroneacetate for the use of ovulation suppression in in-vitro fertilization: A cohort trial. To broadly assess the efficacy of medroxyprogesteroneacetate (MPA) for ovulatory suppression during in vitro stimulation (IVF) when compared to gonadotropin releasing hormone (GnRH) antagonist cycles DESIGN: Cohort Trial SETTING: A single academic-affiliated private fertility
Effects of depot medroxyprogesteroneacetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial. Robust information on relative effects of hormonal contraceptives on endogenous androgens is important for understanding beneficial and adverse effects, method choice and development of new methods. In this ancillary study at the East London, South Africa site of the ECHO multicentre randomized trial, we compared effects of three contraceptive methods on serum androgen levels among contraceptive users aged 18 to 35 years. Participants were allocated by centrally-managed randomization to open label depot medroxyprogesteroneacetate (DMPA-IM), copper intrauterine device (IUD
Exposure of antral follicles to medroxyprogesteroneacetate during stimulation does not cause molecular perturbations in gonadotropin-responsiveness and steroidogenic function of granulosa cells in progestin-primed cycles. Does medroxyprogesteroneacetate (MPA) exposure in progestin-primed ovarian stimulation (PPOS) cycles cause molecular perturbations in the steroidogenic function
Oncologic and pregnancy outcomes of fertility-sparing treatment with medroxyprogesteroneacetate in women with premalignant and malignant endometrial lesions: A case series. Current trends of delaying childbearing and the increasing incidence of endometrial cancer in nulliparous woman necessitate research and development of fertility sparing treatments. Hormonal therapy with progestins offers an alternative to surgical treatment for a select group of patients of reproductive-age, who wish to preserve their reproductive potential. The study evaluates the effectiveness of medroxyprogesteroneacetate therapy in patients with early-stage endometrial cancer, atypical endometrial hyperplasia or atypical polypoid adenomyoma, seeking to preserve fertility. This prospective case series encompasses nine
Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estrogens/MedroxyprogesteroneAcetate on Breast Cancer Gene Expression in Healthy Postmenopausal Women. Recent studies suggest estradiol (E)/natural progesterone (P) confers less breast cancer risk compared with conjugated equine estrogens (CEE)/synthetic progestogens. We investigate if could provide some explanation. This study is a subset of a monocentric, 2-way, open observer-blinded, phase 4 randomized controlled trial on healthy postmenopausal women with climacteric symptoms (ClinicalTrials.gov; EUCTR-2005/001016-51). Study medication was two 28-day cycles of sequential hormone treatment with oral 0.625 mg CEE and 5 mg of oral medroxyprogesteroneacetate (MPA) or 1.5 mg E as percutaneous gel/day with the addition of 200 mg
A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesteroneacetate contraceptive formulation. This study aimed to evaluate and compare local tolerability of investigational drug TV-46046 and reference drug Depo-subQ Provera 104, both containing medroxyprogesteroneacetate (MPA) as an active ingredient. We conducted
MedroxyprogesteroneAcetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles. To compare the effect of Medroxyprogesteroneacetate versus Gonadotropin releasing hormone antagonist for the prevention of premature luteinizing hormone (LH) surge in infertile hyper-responder women undergoing controlled ovarian stimulation for in vitro fertilization (IVF) /intracytoplasmic sperm injection (ICSI) cycles. One hundred infertile hyper-responder women who were candidate for IVF/ICSI were randomly assigned into two groups. Group 1 was given 20 mg Medroxyprogesteroneacetate from day 1 of the menstrual cycle till trigger day. Group 2 was given GnRH
Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot MedroxyprogesteroneAcetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial found no substantial difference in HIV acquisition risk between women randomised to injectable intramuscular depot medroxyprogesteroneacetate (DMPA-IM), copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. We evaluated post-randomization sexual behavior using an objective marker of condomless vaginal sex in a subset of participants. We conducted a sub-study among 458 ECHO participants at three sites (Cape Town, Johannesburg, Kisumu) to evaluate the frequency of condomless vaginal sex
Patient's experience and satisfaction with self-administered subcutaneous depot medroxyprogesteroneacetate use during the first year of COVID-19. Self-administered subcutaneous (SC) depot medroxyprogesteroneacetate (DMPA) can improve contraception access by eliminating a health center visit for administration. For patients at our New York City health centers who were offered a switch to self
Comparison of the effectiveness of Dienogest with medroxyprogesteroneacetate in the treatment of pelvic pain and recurrence of endometriosis after laparoscopic surgery. The aim of this study was to compare the effects of Dienogest and medroxyprogesteroneacetate (MPA) on the recurrence of endometriosis lesions and clinical symptoms in women undergoing laparoscopic surgery. This single center
[Comparison of the effects and safety of dydrogesterone and medroxyprogesteroneacetate on endometrial hyperplasia without atypia: a randomized controlled non-inferior phase Ⅲ clinical study]. To compare the effects and safety of dydrogesterone (DG) and medroxyprogesteroneacetate (MPA) on the treatment in patients with endometrial hyperplasia without atypia (EH). This was a single-center
The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot MedroxyprogesteroneAcetate, or Levonorgestrel Implant. The ECHO trial randomized women to intramuscular depot medroxyprogesteroneacetate (DMPA-IM), levonorgestrel implant (LNG-implant), or copper intrauterine device (Cu-IUD). In a substudy of the ECHO trial, we tested the hypothesis
Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot MedroxyprogesteroneAcetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial. Globally, women have higher herpes simplex virus type 2 (HSV-2) prevalence than men; data from observational studies suggest a possible association of HSV-2 acquisition with use of intramuscular depot medroxyprogesteroneacetate (DMPA-IM). Within a randomized trial of the effect of 3 contraceptive methods-DMPA-IM, a copper intrauterine device (IUD), and a levonorgestrel (LNG) implant-on human immunodeficiency virus (HIV) acquisition, we assessed HSV-2 acquisition. HSV-2 and HIV seronegative women, aged 16-35 years, and seeking effective contraception were followed for 12-18 months at 12